Assembly Biosciences (NASDAQ:ASMB) Rating Reiterated by HC Wainwright

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “neutral” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports.

Separately, StockNews.com upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, May 10th.

Assembly Biosciences Stock Performance

NASDAQ:ASMB opened at $14.88 on Thursday. Assembly Biosciences has a 12 month low of $7.69 and a 12 month high of $20.04. The company’s 50-day moving average price is $14.26 and its two-hundred day moving average price is $12.35.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($1.66) EPS for the quarter, topping analysts’ consensus estimates of ($2.74) by $1.08. The company had revenue of $5.79 million for the quarter. As a group, analysts forecast that Assembly Biosciences will post -12.65 EPS for the current fiscal year.

Insider Transactions at Assembly Biosciences

In other Assembly Biosciences news, Director John G. Mchutchison sold 2,117 shares of the stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $14.93, for a total value of $31,606.81. Following the transaction, the director now owns 19,104 shares of the company’s stock, valued at $285,222.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 7,580 shares of company stock worth $102,979 in the last three months. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC acquired a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned approximately 0.08% of Assembly Biosciences as of its most recent SEC filing. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.